Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics (PRQR) Total Non-Current Liabilities (2016 - 2025)

ProQR Therapeutics' Total Non-Current Liabilities history spans 6 years, with the latest figure at $36.0 million for Q4 2025.

  • On a quarterly basis, Total Non-Current Liabilities fell 16.77% to $36.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $36.0 million, a 16.77% decrease, with the full-year FY2025 number at $36.0 million, down 16.77% from a year prior.
  • Total Non-Current Liabilities hit $36.0 million in Q4 2025 for ProQR Therapeutics, down from $43.3 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for PRQR hit a ceiling of $85.3 million in Q4 2022 and a floor of $36.0 million in Q4 2025.
  • Historically, Total Non-Current Liabilities has averaged $62.1 million across 5 years, with a median of $67.0 million in 2023.
  • Biggest five-year swings in Total Non-Current Liabilities: skyrocketed 106.91% in 2021 and later tumbled 35.43% in 2024.
  • Tracing PRQR's Total Non-Current Liabilities over 5 years: stood at $78.7 million in 2021, then rose by 8.51% to $85.3 million in 2022, then dropped by 21.47% to $67.0 million in 2023, then plummeted by 35.43% to $43.3 million in 2024, then decreased by 16.77% to $36.0 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for PRQR at $36.0 million in Q4 2025, $43.3 million in Q4 2024, and $67.0 million in Q4 2023.